Edition:
United Kingdom

Aevi Genomic Medicine Inc (GNMX.OQ)

GNMX.OQ on NASDAQ Stock Exchange Global Market

1.67USD
22 May 2018
Change (% chg)

$-0.03 (-1.76%)
Prev Close
$1.70
Open
$1.67
Day's High
$1.67
Day's Low
$1.67
Volume
2,253
Avg. Vol
33,393
52-wk High
$2.64
52-wk Low
$0.98

Chart for

About

Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $98.50
Shares Outstanding(Mil.): 59.34
Dividend: --
Yield (%): --

Financials

  GNMX.OQ Industry Sector
P/E (TTM): -- 222.84 32.59
EPS (TTM): -0.72 -- --
ROI: -136.07 -7.75 12.60
ROE: -136.07 -10.55 14.49

BRIEF-Aevi Genomic Medicine Files For Mixed Shelf Of Up To $50 Mln

* AEVI GENOMIC MEDICINE INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING Source text: (https://bit.ly/2IjWI5B) Further company coverage:

15 May 2018

BRIEF-Aevi Genomic Medicine Reports Q4 Loss Per Share $0.13

* AEVI GENOMIC MEDICINE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

13 Mar 2018

BRIEF-Aevi Genomic Medicine Expands Collaboration With Kyowa Hakko Kirin Co

* AEVI GENOMIC MEDICINE INC - EXPANDED COLLABORATION WITH KYOWA HAKKO KIRIN CO LTD

07 Mar 2018

BRIEF-Aevi Genomic Medicine Files For Resale Of Up To 26.2 Mln Shares Of Co's Common Stock By Selling Stockholders

* AEVI GENOMIC MEDICINE INC FILES FOR RESALE OF UP TO 26.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text - http://bit.ly/2kEddlX Further company coverage:

08 Dec 2017

BRIEF-Aevi Genomic Medicine Announces New Appointment To Its Board Of Directors

* AEVI GENOMIC MEDICINE ANNOUNCES NEW APPOINTMENT TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

04 Dec 2017

Competitors

Earnings vs. Estimates